8-K: MacroGenics Announces Vobramitamab Duocarmazine Phase 2 Trial Update and ESMO Presentation

MacroGenics will present updated clinical data from its Phase 2 TAMARACK trial of vobramitamab duocarmazine for metastatic castration-resistant prostate cancer at the ESMO Congress in September.

Summary

• MacroGenics has announced an upcoming poster presentation at the European Society for Medical Oncology (ESMO) Congress 2024 in September, featuring updated data from the Phase 2 TAMARACK trial of vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC).
• The presentation will include a pre-defined landmark primary endpoint of the 6-month radiographic progression-free survival (rPFS) rate, along with updated safety data.
• The abstract submitted to ESMO was based on an April 12 data cut-off, while the poster will include additional data from a July 9 data cut-off.
• The company has discontinued treatment for remaining TAMARACK study participants who were eligible for further dosing, following a review of the totality of data, including efficacy and emerging adverse events associated with prolonged exposure.
• Most of the participants had received at least 8 cycles of vobra duo.
• MacroGenics plans to host an investor update call after the ESMO presentation in September to discuss the TAMARACK data and potential next steps for the vobra duo program.
• The company expects to release its financial results and corporate progress on or around August 6, 2024.
• The company completed enrollment for the TAMARACK study in the fourth quarter of 2023.
• The company expects to have mature efficacy findings, including median rPFS, later in the second half of 2024 and plans to present the data at a subsequent medical conference.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is presenting data at a major conference, but the discontinuation of treatment for some participants due to adverse events is a concern. The future of the program depends on the data presented at ESMO.

Positives

• The company is presenting updated safety and efficacy data at a major medical conference.
• The company has completed enrollment for the TAMARACK study.
• The company is committed to fully assessing the potential of vobra duo in mCRPC through rigorous evaluation of the data.

Negatives

• Treatment was discontinued for remaining eligible participants due to emerging adverse events associated with prolonged exposure.
• The company has entered a quiet period and will not be hosting a conference call to discuss its financial results or corporate progress for the quarter ended June 30, 2024.

Risks

• The discontinuation of treatment for remaining participants raises concerns about the safety profile of vobra duo with prolonged exposure.
• The company is in a quiet period, limiting communication with investors until after the ESMO presentation.
• The future of the vobra duo program depends on the data presented at ESMO and subsequent analysis.

Future Outlook

The company plans to present mature efficacy findings, including median rPFS, later in the second half of 2024 and will use the ESMO data to inform future study designs. They will also host an investor call after the ESMO presentation to discuss the TAMARACK data and potential next steps for the vobra duo program.

Management Comments

• We are pleased to have the opportunity to present updated safety and efficacy data from our TAMARACK trial at the upcoming ESMO Congress in September, said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics.
• We believe that these data will give us valuable insights to inform potential next steps for the vobra duo program in mCRPC, and we look forward to providing additional perspective to the investment community following our ESMO presentation.
• Patient safety is our top priority, and having reached the studys primary endpoint, we decided to discontinue additional dosing for the remaining TAMARACK participants who had not yet completed treatment, continued Dr. Koenig.

Industry Context

The development of antibody-drug conjugates (ADCs) like vobramitamab duocarmazine is a growing area of focus in cancer therapeutics, particularly for solid tumors. The results of the TAMARACK trial will be closely watched by the oncology community and competitors in the ADC space.

Comparison to Industry Standards

• The 6-month rPFS rate is a common endpoint in prostate cancer trials, and the results will be compared to other treatments in the mCRPC space, such as enzalutamide, abiraterone, and docetaxel.
• Companies like Astellas and Pfizer, which market enzalutamide and abiraterone respectively, are key competitors in the mCRPC market.
• The safety profile of vobramitamab duocarmazine will be compared to other ADCs in development, such as those targeting HER2 or Trop2, to assess its tolerability.

Stakeholder Impact

• Shareholders will be interested in the clinical data and the future of the vobra duo program.
• Patients with mCRPC may benefit from the development of new treatment options.
• Employees of MacroGenics are involved in the development and commercialization of the drug.
• The company's collaborators will be interested in the progress of the program.

Next Steps

• MacroGenics will present the TAMARACK trial data at the ESMO Congress in September.
• The company will publish the poster on its website around September 15, 2024.
• An investor update call will be held after the ESMO presentation.
• The company will release its financial results and corporate progress on or around August 6, 2024.
• The company will complete follow-up for the TAMARACK trial before year-end.
• The company will present mature efficacy findings, including median rPFS, at a subsequent medical conference.

Key Dates

Keywords

vobramitamab duocarmazine, mCRPC, prostate cancer, TAMARACK, ESMO, antibody-drug conjugate, ADC, B7-H3, clinical trial, rPFS